1511 related articles for article (PubMed ID: 30607788)
21. RHBDD1 promotes proliferation, migration, invasion and EMT in renal cell carcinoma via the EGFR/AKT signaling pathway.
Li M; Cai L; Wang X; Yu Y; Jian W; Bao G; Gao Z; Guo J; Zhang J; Li C; Zhang C
Mol Med Rep; 2021 Dec; 24(6):. PubMed ID: 34581421
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
23. Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway.
Zeng L; Liao Q; Zou Z; Wen Y; Wang J; Liu C; He Q; Weng N; Zeng J; Tang H; Fang R; Lei Z; Tang Z; Yang X; Cui S
Cell Physiol Biochem; 2018; 51(3):1221-1236. PubMed ID: 30481766
[TBL] [Abstract][Full Text] [Related]
24. LncRNA TP73-AS1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Clear Cell Renal Cell Carcinoma Through Repressing KISS1 Expression and Inactivation of PI3K/Akt/mTOR Signaling Pathway.
Liu G; Zhao X; Zhou J; Cheng X; Ye Z; Ji Z
Cell Physiol Biochem; 2018; 48(1):371-384. PubMed ID: 30016766
[TBL] [Abstract][Full Text] [Related]
25. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
Wang H; Zhang C; Xu L; Zang K; Ning Z; Jiang F; Chi H; Zhu X; Meng Z
Oncotarget; 2016 Apr; 7(15):20193-208. PubMed ID: 26958938
[TBL] [Abstract][Full Text] [Related]
26. γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
Li Y; Wu T; Wang Y; Yang L; Hu C; Chen L; Wu S
Gynecol Oncol; 2018 Apr; 149(1):163-172. PubMed ID: 29429592
[TBL] [Abstract][Full Text] [Related]
27. Daidzin targets epithelial-to-mesenchymal transition process by attenuating manganese superoxide dismutase expression and PI3K/Akt/mTOR activation in tumor cells.
Yang MH; Jung SH; Um JY; Kumar AP; Sethi G; Ahn KS
Life Sci; 2022 Apr; 295():120395. PubMed ID: 35181309
[TBL] [Abstract][Full Text] [Related]
28. NCAM regulates the proliferation, apoptosis, autophagy, EMT, and migration of human melanoma cells via the Src/Akt/mTOR/cofilin signaling pathway.
Li J; Yang R; Yang H; Chen S; Wang L; Li M; Yang S; Feng Z; Bi J
J Cell Biochem; 2020 Feb; 121(2):1192-1204. PubMed ID: 31468584
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-203 inhibits epithelial-mesenchymal transition, migration, and invasion of renal cell carcinoma cells via the inactivation of the PI3K/AKT signaling pathway by inhibiting CAV1.
Han N; Li H; Wang H
Cell Adh Migr; 2020 Dec; 14(1):227-241. PubMed ID: 32990143
[TBL] [Abstract][Full Text] [Related]
30. Klotho suppresses tumor progression via inhibiting PI3K/Akt/GSK3β/Snail signaling in renal cell carcinoma.
Zhu Y; Xu L; Zhang J; Xu W; Liu Y; Yin H; Lv T; An H; Liu L; He H; Zhang H; Liu J; Xu J; Lin Z
Cancer Sci; 2013 Jun; 104(6):663-71. PubMed ID: 23433103
[TBL] [Abstract][Full Text] [Related]
31. Cucurbitacin E inhibits esophageal carcinoma cell proliferation, migration, and invasion by suppressing Rac1 expression through PI3K/AKT/mTOR pathway.
Zhang L; Liang H; Xin Y
Anticancer Drugs; 2020 Sep; 31(8):847-855. PubMed ID: 32568828
[TBL] [Abstract][Full Text] [Related]
32. Metastasis suppressor protein 1 regulated by PTEN suppresses invasion, migration, and EMT of gastric carcinoma by inactivating PI3K/AKT signaling.
Wang H; Zhao Y; Cao L; Zhang J; Wang Y; Xu M
J Cell Biochem; 2019 Mar; 120(3):3447-3454. PubMed ID: 30246429
[TBL] [Abstract][Full Text] [Related]
33. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Wang Z; Qu L; Deng B; Sun X; Wu S; Liao J; Fan J; Peng Z
Sci Rep; 2016 Sep; 6():33205. PubMed ID: 27628214
[TBL] [Abstract][Full Text] [Related]
34. TRIM26 inhibits clear cell renal cell carcinoma progression through destabilizing ETK and thus inactivation of AKT/mTOR signaling.
Zheng D; Ning J; Deng H; Ruan Y; Cheng F
J Transl Med; 2024 May; 22(1):481. PubMed ID: 38773612
[TBL] [Abstract][Full Text] [Related]
35. Galectin-1 Overexpression Activates the FAK/PI3K/AKT/mTOR Pathway and Is Correlated with Upper Urinary Urothelial Carcinoma Progression and Survival.
Su YL; Luo HL; Huang CC; Liu TT; Huang EY; Sung MT; Lin JJ; Chiang PH; Chen YT; Kang CH; Cheng YT
Cells; 2020 Mar; 9(4):. PubMed ID: 32225123
[TBL] [Abstract][Full Text] [Related]
36. miR-215-5p is an anticancer gene in multiple myeloma by targeting RUNX1 and deactivating the PI3K/AKT/mTOR pathway.
Liu S; Zhang Y; Huang C; Lin S
J Cell Biochem; 2020 Feb; 121(2):1475-1490. PubMed ID: 31498483
[TBL] [Abstract][Full Text] [Related]
37. NDRG2 is involved in the oncogenic properties of renal cell carcinoma and its loss is a novel independent poor prognostic factor after nephrectomy.
Liang ZL; Kang K; Yoon S; Huang SM; Lim JS; Kim JM; Lim JS; Lee HJ
Ann Surg Oncol; 2012 Aug; 19(8):2763-72. PubMed ID: 22246425
[TBL] [Abstract][Full Text] [Related]
38. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
[TBL] [Abstract][Full Text] [Related]
39. WSTF promotes proliferation and invasion of lung cancer cells by inducing EMT via PI3K/Akt and IL-6/STAT3 signaling pathways.
Meng J; Zhang XT; Liu XL; Fan L; Li C; Sun Y; Liang XH; Wang JB; Mei QB; Zhang F; Zhang T
Cell Signal; 2016 Nov; 28(11):1673-82. PubMed ID: 27449264
[TBL] [Abstract][Full Text] [Related]
40. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
